Will Novo Nordisk raise its full-year 2026 sales growth guidance by 10 November 2026?
Posted 2026-10-29 — 12 days before the deadline, stated before the outcome.
Novo Nordisk is a Danish multinational pharmaceutical company known for its diabetes and obesity treatments. Public companies periodically update financial forecasts to reflect current market conditions and product performance.
The claim
Novo Nordisk raises its full-year 2026 sales growth guidance by 2026-11-10.
Reasoning trace
- Lilly reports Q3 revenue +39% and raises 2026 guidance
- Investors read through to GLP-1 class demand, lifting Novo's shares
- Novo Nordisk raises its 2026 sales growth guidance
Evidence so far
2 confirming · 0 denying signals · 4 verified · 2 broken assumptions. The evidence itself is part of the full dossier.
Probability history
Updated 14 times since mint (last on 2026-11-05) — 18% at mint → 83% today.
What to watch
- milestone Novo Nordisk files a Form 8-K with the SEC disclosing material non-public information regarding a change in financial guidance
- precondition Novo Nordisk releases its Q3 2026 financial results and operational update
- precondition Eli Lilly publishes its Q3 2026 earnings report showing significant revenue growth (e.g., +39% YoY) and/or raises its own 2026 guidance
The full dossier behind this prediction — the evidence trail, the risk analysis, the monetization scenarios — is available on request: [email protected].
Probabilities are calibrated against the system's own resolved history; after the deadline the outcome is resolved and audited — including the calls we get wrong. Nothing on this page is investment advice.